Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine, thalidomide, and dexamethasone dose-escalation study in relapsed/refractory multiple myeloma
ISRCTN90889843Phase 2Completed
- Sponsor
- University of Leeds
- Start
- Jan 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 2, open-label trial of bendamustine, thalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by University of Leeds. Primary endpoints: Partial response or better within six cycles, Ability to receive second bendamustine cycle on schedule and 1 more. Started Jan 2012; status: completed.
02
Drugs
bendamustinethalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN90889843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN90889843.